Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Trump’s FDA Pick Refuses to Say IUDs Don’t Cause Abortions

This article has been republished from Autonomy News, a worker-owned publication covering reproductive rights and justice. Follow Autonomy News on Instagram, Bluesky, TikTok, Threads, and LinkedIn. Dr. Heidi Overton, Donald Trump’s nominee to be the next head of the FDA, opened a Wednesday confirmation hearing before the Senate’s Health, Education, Labor and Pensions (HELP) committee by thanking…

Dr. Heidi Overton, Donald Trump's nominee to lead the FDA, faced intense questioning during her confirmation hearing. Murray pressed Overton about her stance on IUDs, asking if she agreed that an intrauterine device (IUD) is an abortifacient. Overton refused to answer, stating that if confirmed, she would be "fully briefed on all their prior decisions and make determinations according to the standards of safety and efficacy."

The nominee also faced questions about mifepristone, an abortion medication, stating that it "has met the safety and efficacy standard" as per FDA approval. However, Murray pointed out that scientific evidence shows mifepristone is safe and effective. Overton defended her stance, saying she is driven by data and that the paper was written "after a change was made at the FDA in how that medication was accessed."

She also mentioned an ongoing FDA review, which she said is "very important." Democrats called for Overton to recuse herself from the mifepristone review due to her past comments. Overton's comments on mifepristone and IUDs have raised concerns about her potential influence on abortion access if confirmed.

Written by urgent.news from Mother Jones's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at motherjones.com →

More in Health & Medicine

JNC Targets Bigger Molecules with Cellufine

JNC is using BioProcess International 2026 to spotlight Cellufine and its emerging MLP chromatography media, developed to address purification challenges posed by viral vectors, vaccines, and other…

  • JNC presents Cellufine chromatography portfolio at BioProcess International 2026
  • MLP products use large-pore bead architecture for bulky biological targets

More from Thursday 24 September →